At the ASCO 2019 annual meeting, Janice Mehnert discusses GITR as an emerging novel checkpoint in immunotherapy as well as sharing the findings from the recent study investigating the compound MK-4166 (NCT02132754) and considering the next steps in its clinical development.
1. What are the limitations of current immunotherapies in the treatment of solid tumours? (0:04)
2. What is the rationale for targeting glucocorticoid-induced tumour necrosis factor receptor (GITR)? (0:43)
3. What were the efficacy and safety findings of the recent study investigating MK-4166 as monotherapy or with pembrolizumab in patients with advanced solid tumours? (1:40)
4. What will be the next step in the clinical development of MK-4166? (2:39)
5. What other costimulatory receptors appear to be promising therapeutic targets? (3:23)
Speaker disclosure: Janice Mehnert has acted as a consultant for Merck & Co and participated in advisory boards for BMS, Reserit, Merck, Incyte and AstraZeneca.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
Share this Video
Related Videos In Haematological Malignancies
Andreas Hochhaus, ASH 2020 – The ASCEMBL Study and Asciminib in CML
touchONCOLOGY meets with Prof. Andreas Hochhaus to discuss the clinical development of asciminib and its potential as a therapy for chronic myeloid leukaemia. The abstract ‘Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic […]
Othman Al-Sawaf, ASH 2020 – Venetoclax-obinutuzumab and the CLL14 Trial
Dr Othman Al-Sawaf joins touchONCOLOGY to discuss the CLL14 trial and the impact of venetoclax-obinutuzumab treatment on clonal growth and the potential of its use in chronic lymphocytic leukaemia. The abstract ‘Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial’ (Abstract number 127) was presented at the 62nd American Society […]
Shaji Kumar, ASH 2020 – Highlights from ASH 2020
It was a pleasure to speak with our Editor-in-Chief, Shaji Kumar (Mayo Clinic, Rochester, MN, USA) to discuss the use of MEDI2228 (Clinical Trial Identifier: NCT03489525) and anti-BCMA CAR-T cells (Clinical Trial Identifier: NCT03915184) in the treatment of patients with relapsed/refractory multiple myeloma and to find out his personal highlights from this year’s congress. The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!